Kyverna Therapeutics, Inc.

2024 started with early optimism at a potential rebound in deal-making with many unpartnered life sciences assets in Phase III or later (and a lot more at earlier stages), more than $800bn available i

Artiva Biotherapeutics, Inc. ’s initial public offering late on 18 July reflected the mixed bag that the IPO market has become. To get the offering through the IPO window at a time when first-time off

Alumis, Inc. planned to raise between $282.4m and $317.7m in the last biopharmaceutical initial public offering in the US during the first half of 2024, but instead grossed $250m on 27 June from the

Companies looking to bring the first CAR-T treatment for autoimmune diseases to market will present their latest data at the European Alliance of Associations for Rheumatology (EULAR) meeting this wee